Company research
SIGA TECHNOLOGIES INC
CIK 1010086Updated Sep 24, 2026
SecuritySIGA · NASDAQ · equity
Name history
SIGA PHARMACEUTICALS INC · through May 25, 2000
SIGA price & chart
Loading TradingView…
NASDAQ:SIGA on TradingView ↗About the company
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
In the news
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
DEFA14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 219,467,434Source | 244,337,026Source | 254,352,855Source | 195,035,923Source |
| Property, Plant and Equipment, NetUSD | 1,090,824Source | 1,298,423Source | 1,331,708Source | 1,848,314Source |
| GoodwillUSD | 898,334Source | 898,334Source | 898,334Source | 898,334Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 154,966,414Source | 155,400,262Source | 150,145,844Source | 98,790,622Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,263,736Source | 21,166,129Source | 21,130,951Source | 45,406,960Source |
| Inventory, NetUSD | 49,054,873Source | 49,563,880Source | 64,218,337Source | 39,273,090Source |
| Assets, CurrentUSD | 212,856,864Source | 231,044,884Source | 238,991,160Source | 185,786,344Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,571,841Source | 4,914,613Source | 3,496,028Source | 2,315,672Source |
| Other Assets, NoncurrentUSD | 192,893Source | 240,683Source | 2,083,535Source | 252,546Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 20,645,862Source | 28,532,263Source | 57,493,948Source | 24,875,881Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 7,161Source | 7,140Source | 7,109Source | 7,268Source |
| Retained Earnings (Accumulated Deficit)USD | -43,070,803Source | -22,838,012Source | -38,943,622Source | -63,804,993Source |
| Stockholders' Equity Attributable to ParentUSD | 198,821,572Source | 215,804,763Source | 196,858,907Source | 170,160,042Source |
| Additional Paid in Capital, Common StockUSD | 241,885,214Source | 238,635,635Source | 235,795,420Source | 233,957,767Source |
| Liabilities and EquityUSD | 219,467,434Source | 244,337,026Source | 254,352,855Source | 195,035,923Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 17,992,579Source | 25,331,613Source | 54,117,745Source | 21,517,721Source |
| Operating Lease, Liability, CurrentUSD | 595,169Source | 546,820Source | — | — |
| Accounts Payable, CurrentUSD | 824,522Source | 1,340,337Source | 1,456,316Source | 3,355,268Source |
| Operating Lease, Liability, NoncurrentUSD | 200,000Source | 800,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 2,653,283Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,520,057Source | 5,640,110Source | 10,181,810Source | 16,852,781Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 562,607Source | 538,421Source | 538,293Source | 517,643Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,683,363Source | 3,640,141Source | 2,052,462Source | 1,779,310Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -17,902,393Source | 35,178Source | -24,276,009Source | -38,243,490Source |
| Increase (Decrease) in InventoriesUSD | 846,312Source | -15,342,653Source | 25,524,485Source | 19,964,183Source |
| Deferred Income Tax Expense (Benefit)USD | 6,426,182Source | 193,416Source | -4,797,733Source | -3,827,778Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 43,471,453Source | 48,761,807Source | 94,799,331Source | 41,611,062Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -355,009Source | -42,450Source | -21,686Source | 0Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 433,763Source | 799,895Source | 214,794Source | 12,533Source |
| Payments for Repurchase of Common StockUSD | 0Source | 0Source | 11,072,511Source | 13,006,331Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -43,550,292Source | -43,464,939Source | -43,422,423Source | -45,959,259Source |
| Dividends paid | — | — | — | — |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 154,966,414Source | 155,400,262Source | 150,145,844Source | 98,790,622Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 8,200,973Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,700,000Source | 3,600,000Source | 2,100,000Source | 1,800,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| GoodwillUSD | 898,334Source | 898,334Source | 898,334Source | 898,334Source |
| Income Tax Expense (Benefit)USD | 7,102,877Source | 16,856,174Source | 19,707,847Source | 10,227,926Source |
| Inventory Write-downUSD | 1,800,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 23,279,143Source | 59,214,216Source | 68,068,826Source | 33,904,806Source |
| Nonoperating Income (Expense)USD | 6,679,864Source | 6,087,116Source | 4,155,508Source | 1,031,903Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 94,574,902Source | 138,719,350Source | 139,917,220Source | 110,775,610Source |
| Cost of RevenueUSD | 29,703,893Source | 31,289,229Source | 17,825,090Source | 10,432,561Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 21,212,694Source | 25,136,050Source | 22,043,023Source | 35,117,241Source |
| Operating Income (Loss)USD | 23,702,156Source | 69,983,274Source | 83,621,165Source | 42,700,166Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 30,382,020Source | 76,070,390Source | 87,776,673Source | 44,132,732Source |
| Income Tax Expense (Benefit)USD | 7,102,877Source | 16,856,174Source | 19,707,847Source | 10,227,926Source |
| Net Income (Loss) Attributable to ParentUSD | 23,279,143Source | 59,214,216Source | 68,068,826Source | 33,904,806Source |
| Earnings Per Share, BasicUSD per share | 0.33Source | 0.83Source | 0.95Source | 0.46Source |
| Earnings Per Share, DilutedUSD per share | 0.32Source | 0.82Source | 0.95Source | 0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 71,528,043Source | 71,253,172Source | 71,362,209Source | 72,929,550Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 71,867,627Source | 71,905,712Source | 71,679,270Source | 73,546,501Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 70,872,746Source | 68,736,076Source | 56,296,055Source | 68,075,444Source |
| Current Income Tax Expense (Benefit)USD | 676,695Source | 16,662,758Source | 24,505,580Source | 14,055,704Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 30,332,374Source | — | — | — |
| Interest ExpenseUSD | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | 6,679,864Source | 6,087,116Source | 4,155,508Source | 1,031,903Source |
| Research and Development ExpenseUSD | 19,956,159Source | 12,310,797Source | 16,427,942Source | 22,525,642Source |
Filing attachments
ef20079446_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ef20079446_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 $37 Million of TPOXX Sales Generated in the Second Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 6, 2026 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2026. “In the second quarter, …
Read attachment ↗ef20072552_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 ef20072552_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Press Release SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update On Track to Deliver $13 Million of Oral TPOXX to an International Customer in Second Quarter Expect to Deliver $26 Million of IV TPOXX to the U.S. Government Strategic National Stockpile by End of the Third Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 7, 2026 (GLOBE…
Read attachment ↗ef20067458_ex99-1.htm · 8-K · 2026-03-10
EX-99.1 2 ef20067458_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, to…
Read attachment ↗ef20058429_ex99-1.htm · 8-K · 2025-11-06
EX-99.1 2 ef20058429_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, November 6, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million…
Read attachment ↗ef20053161_ex99-1.htm · 8-K · 2025-08-05
EX-99.1 2 ef20053161_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025 Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 5, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commerc…
Read attachment ↗ef20048574_ex99-1.htm · 8-K · 2025-05-08
EX-99.1 2 ef20048574_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2025 Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 8, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage …
Read attachment ↗